Parainfluenza virus type 3 (PIV3) is associated with a high mortality rate in BMT recipients with lower respiratory tract infections. We describe nine patients with hematological malignancies (five having undergone either allogeneic or autologous stem cell transplantation) identified as having PIV3 infection during a 2-month period in a Hematology Unit. Four patients with infiltrates on chest radiograph received intravenous ribavirin therapy; all survived. The infection was community-acquired in two patients, while nosocomial origin of the disease was evident, or presumed, in the remaining seven. The policy implemented to control the spread of PIV3 was as follows: (1) nasopharyngeal samples for antigen detection were obtained from all patients presenting with respiratory symptoms; (2) all diagnosed (or suspected) PIV3-positive hematological patients were nursed following contact isolation precautions, preferably in the Infectious Diseases Unit; and (3) staff were given further education on hospital hygiene. Our experience shows that it may be possible to avoid mortality for PIV3 lower respiratory tract infection in immunocompromised patients by early commencement of intravenous ribavirin. It is also possible, even without closing the ward, to contain nosocomial spread of PIV3 by implementing systematic nasopharyngeal sampling for rapid diagnostics, and by strict adherence to cohorting and contact isolation precautions. Bone Marrow Transplantation (2001) 27, 295-300.
piratory pathogen. Lower respiratory tract infections caused by PIV3 have been described especially in patients undergoing BMT, [4] [5] [6] [7] [8] [9] but also in heart, liver, kidney, and lung transplant recipients. [10] [11] [12] In these patients, PIV3 infections have been associated with a high mortality rate of up to 50%. 7 According to a few clinical studies, antiviral treatment with ribavirin may improve the outcome of parainfluenza infection in hematology patients. 4, 13 In the majority of the cases described, however, ribavirin has been administered in aerosolized form, 4, 5, 9, 12 while only very few studies have addressed the use of ribavirin in the intravenous or oral form. 13 There are several reports showing that introduction of PIV3 into hospital may lead to outbreaks in transplant units and on pediatric wards. 8, [14] [15] [16] Thus, in the hospital environment, the possibility of nosocomial spread of PIV3 should always be taken into account.
In November 1998, three cases of PIV3 were detected among patients treated in the Hematology Unit of a university hospital in Finland. Aware of the often serious nature of this infection in immunocompromised patients, we endeavored during the following months to obtain a rapid etiologic diagnosis of PIV3 in hematology patients with respiratory symptoms, in order to ensure immediate commencement of antiviral therapy when needed. Here we describe nine PIV3-positive patients identified during this period, and outline the measures implemented to control the spread of PIV3 in our Hematology Unit.
Materials and methods

Institution
The Turku University Hospital is a 1000-bed teaching facility in Finland serving as a tertiary referral center for the southwestern part of the country. In the Hematology Unit, patients undergo allogeneic and autologous stem cell transplants, and receive treatment for acute and chronic leukemias as well as for high grade lymphomas. Transplant patients are nursed in, though not invariably confined to, single rooms. Other hematological patients are nursed in single, double, or three-bed rooms. The Infectious Diseases Unit of the hospital has good facilities for nursing patients following various isolation precautions. As both of these units are situated in the same hospital building and administratively belong to the Department of Medicine, they coop-erate when treating patients with contagious diseases. For example, hematology patients with infections caused by airborne viruses (eg varicella-zoster virus) have been traditionally nursed in the Infectious Diseases Unit.
Viral diagnostics
Viral antigen tests were preferentially used to obtain the etiologic diagnosis in respiratory infections of suspected viral origin. To do so, a nasopharyngeal aspirate was collected from the patient with a disposable mucus extractor. From thrombocytopenic patients, the nasopharyngeal specimen was taken with a sterile cotton swab. Viral antigens for seven common respiratory viruses (parainfluenza types 1, 2 and 3; influenza A and B viruses; adenovirus; and respiratory syncytial virus) were detected at the Department of Virology, Turku University, by time-resolved fluoroimmunoassay as described previously. 17 The sensitivity and specificity of the assay compared to virus isolation is 95% and 96%, and with a confirmatory assay, used for low positive specimens, 96% and 100%. 18 A nasopharyngeal sample was also taken for viral culture from a number of patients. In addition, a viral culture was taken from all bronchoalveolar lavage fluids taken from hematological patients during the study period.
Classification of infections
A patient was defined as having an upper respiratory tract infection in the presence of cough, rhinorrhea, sore throat, and/or sinusitis. A patient was defined as having a lower respiratory tract infection in the presence of dyspnea and hypoxia, and either a new infiltrate on chest radiograph or a positive PIV3 finding from brochoalveolar fluid. In PIV3-positive patients, the infection was designated as nosocomial if clinical symptoms developed after hospitalization for 1 week or longer. The infection was also designated as nosocomial in those patients who developed clinical symptoms at home, but within 2 days of discharge. Infections in patients who developed symptoms at home within 3 to 5 days of discharge were designated as presumably nosocomial. The infection was community-acquired if the patient had not been hospitalized during the weeks preceding the infection.
Ribavirin therapy
Treatment with ribavirin was instituted in all PIV3-positive hematological patients with infiltrates on chest radiograph. Ribavirin was given intravenously 1200 mg a day in three divided doses in patients with normal renal function. In renal insufficiency, the dose was reduced.
Results
From October 1998 to March 1999, 398 nasopharyngeal specimens from 125 hematological patients were tested for the presence of respiratory virus antigens. These included 130 specimens (114 nasopharyngeal samples and 16 bronchoalveolar fluids) from 49 patients, on which a viral culture was also performed. Thirteen specimens from eight patients were positive for PIV3 on antigen detection (two of them also positive in culture), and one additional specimen was positive only on culture. Moreover, 10 nasopharyngeal specimens from eight further patients were positive by antigen detection for viruses other than PIV3: four patients, for influenza B; three for influenza A; two for parainfluenza virus type 1; and one for respiratory syncytial virus.
Clinical characteristics of the nine PIV3-positive are shown in Table 1 . Mean patient age was 48 years (range, 22 to 76 years). All had symptoms of upper respiratory tract infection, and five had, in addition, lower respiratory tract involvement.
Description of the cluster
The nine patents with PIV3 infection were identified between 6 November 1998 and 3 January 1999. Hospitalization periods of the patients and the time points when their respiratory symptoms began and the PIV3-positive specimens were taken are described in Figure 1 . On admission, broad-spectrum intravenous antibacterial therapy was started in all except the final PIV3-positive patient who received peroral erythromycin.
The index case (patient 1) presented at the beginning of November 1998 after having had fever up to 39°C, cough and rhinorrhea for 4 days. On admission, sinus radiograph showed unilateral sinusitis; chest radiograph was normal. Although the patient initially had dyspnea, bronchial obstruction and mild hypoxia, he recovered rapidly without antiviral treatment and was discharged on day 7.
Patient 2 presented with fever and cough in the middle of November. He had been discharged from the Hematology Unit 5 days earlier after the first consolidation treatment for AML. On readmission, chest radiograph showed bilateral interstitial infiltrates, and he received intravenous ribavirin from day 5 until day 10. Patient 3 developed fever and rhinitis in the end of November. He had already been hospitalized in the Hematology Unit for 2 weeks and undergone autologous stem cell transplantation for multiple myeloma. Since his recovery was rapid and the chest radiograph revealed no signs of pneumonia, no antiviral treatment was given.
Patients 4 and 5 were admitted to hospital at the beginning of December. Both of them had been treated in the Hematology Unit in the end of November, and after discharge, both started to suffer from fever, cough and rhinorrhea. Detection of PIV3-antigen positivity in these patients aroused a suspicion of the spread of this virus in the Hematology Unit. In order to prevent further nosocomial virus transmission, the patients were referred to the Infectious Diseases Unit on their third hospital day.
Patients 6 and 7 had received a 1-week course of chemotherapy in the Hematology Unit at the beginning of December. Five days after discharge, they were readmitted on account of fever, cough and rhinorrhea. Patient 6 recovered rapidly without antiviral treatment, while patient 7, with a mild right-sided interstitial infiltration on chest radiograph, received ribavirin therapy.
Patient 8 had been discharged from the Hematology Unit 
Figure 1
Nine hematological patents with PIV3 infection were identified between 6 November 1998, and 3 January 1999. The hospitalization periods of these patients are described as horizontal lines. Symbols: , indicates the time points when the respiratory symptoms of the patients began; ᭹, the time points when the PIV3-positive specimens were taken. The infection was community-acquired in Patients 1 and 9 and nosocomial in patients 3, 6 and 5. The infection was designated as presumably nosocomial in patients 2, 4, 7, and 8.
in the second week of December after hospitalization for 6 weeks, during which he had undergone BMT from an unrelated donor. On his visit to our outpatient clinic 1 week later, he complained of having had fever and rhinorrhea for a few days; the nasopharyngeal aspirate taken proved to be positive for PIV3. At the time of his readmission at the end of December, a chest radiograph showed small bilateral interstitial infiltrates. Antiviral treatment with ribavirin was commenced.
The last new case of PIV3 was detected at the beginning Bone Marrow Transplantation of January 1999, when patient 9 presented with fever, cough, and a sore throat. He had not been hospitalized in the Hematology Unit during the preceding weeks. His disease course was mild, and he was discharged on day 3.
Control measures
After identification of PIV3 infection in patients 4 and 5, we constructed a policy for the control of PIV3 in the Hematology Unit. The measures implemented were as follows:
(1) nasopharyngeal samples were taken from all hematological patients with respiratory symptoms; patients found to be PIV3-positive were nursed in the Infectious Diseases Unit, in private rooms following contact isolation precautions (masks and gowns for direct patient contact and gloves when handling infectious material); (2) all hematology patients presenting with respiratory symptoms were first admitted to the Infectious Diseases Unit, and referred to the Hematology Unit only after results of the nasopharyngeal aspirate proved negative; (3) from 17 December 1998 onwards, a nasopharyngeal specimen was obtained from all patients admitted to the Hematology Unit, even without respiratory symptoms; and (4) due to the long survival of parainfluenza viruses on inanimate surfaces, Chloramine T (Klorilli; Erisan, Espoo, Finland) was adopted for cleaning the ward environment. Moreover, the staff working in the Hematology Unit were given further education on hospital hygiene, focusing particularly on vigorous promotion of hand washing and hand disinfection. Staff were sent off duty if they had symptoms of upper respiratory infection.
Ribavirin therapy
Patients 2 and 7 received one 6-day course of ribavirin, during which recovery was rapid. Due to his profound immunosuppression, patient 5 was treated with intravenous ribavirin for 6 days during his first hospitalization for PIV3, although no obvious infiltrates were detected on chest radiograph. Two days after discharge, he was readmitted with high fever and increasing breathlessness. Based on bilateral interstitial chest radiograph shadowing and continuing PIV3-antigen positivity, intravenous ribavirin for 10 days was reinstituted. Subsequently, when the infiltrates on chest radiograph increased and the PIV antigen was again positive, the patient was given another 10-day course of ribavirin. When patient 8 was admitted with respiratory symptoms, ribavirin was instituted based on the chest infiltrates and the PIV3-antigen positivity found 1 week earlier. Since the infiltrates persisted and the PIV3 antigen was again positive from two successive nasopharyngeal specimens, the patient was given another 2-week course of ribavirin, during which he started to improve and the infiltrates on chest radiograph decreased.
Discussion
PIV3 infections in the nine patients described were identified in our Hematology Unit during a 2-month period. The infection was definitely community-acquired in two patients, and nosocomial in three others. Moreover, we presume that the infection was also nosocomial in the remaining four patients, who started to suffer from respiratory symptoms at home within 4 to 5 days of discharge. This assumption is consistent with the generally accepted incubation period of PIV3: in experimental human infections, the incubation time of PIV3 illness has varied between 3 and 6 days, with an average of 4 days. 19 On epidemiological grounds, the eight first infections identified during 6 weeks could even have been caused by the same PIV3 strain. Before manifestation of the clinical infection, patient 2 had been hospitalized in the Hematology Unit at the same time as the index case during the 5 days he is known to have been PIV3-positive. Furthermore, although all identified PIV3-positive patients were nursed from 4 December 1998 onwards in the Infectious Diseases Unit, simultaneous hospitalization of patients 2-8 in the Hematology Unit at the end of November and beginning of December would have given ample time and opportunity for the nosocomial transmission of PIV3. This may have happened from one patient to another either directly or via the hospital staff.
Although the threat of nosocomial spread of PIV3 in hematological patients is presently well recognized, few previous studies have addressed potential clustering of PIV3 cases in BMT units. Among eight PIV3 infections in BMT recipients at MD Anderson Cancer Center during a 12-month period, the only clustering of infections occurred in four patients over 1 week. 7 Of the 19 PIV3-positive cases diagnosed from 1974 to 1990 in patients undergoing BMT at the University of Minnesota Hospital, six occurred during a 7-month period; three of them, our 5 weeks. 5 Only one paper has described a molecular investigation of the epidemic spread of PIV3 in BMT recipients: of the two successive outbreaks in the BMT unit at the Hammersmith Hospital, the first involving seven patients and lasting 4 months was caused by four different PIV3 strains, and the second involving eight patients and lasting 1 month, by one defined PIV3 strain. 8 The latter outbreak was stopped only after closure of the ward. 8 We were fortunate enough to contain the imminent outbreak without closing the ward, by systematic nasopharyngeal sampling of patients and by prompt implementation of strict hygienic measures, when a suspicion arose that PIV3 was spreading in the Hematology Unit. Unlike many other viruses, PIV3 is characterized by prolonged shedding: 20, 21 PVI3 has been isolated up to 5 weeks after the onset of the illness, in otherwise healthy children, 22 and in BMT recipients, the shedding may continue for as long as 4 months, despite treatment with ribavirin. 8 In fact, prolonged shedding may be essential for the development and persistence of outbreaks by PIV3 in hospital or in the community. Since parainfluenza viruses are transmitted by direct person-to-person contact or by large droplet spread, it is possible to control nosocomial virus transmission by contact isolation and droplet precautions. The staff of the Hematology Unit, being used to maintaining high-level hospital hygiene in all patient care, are proficient in following various isolation precautions. Moreover, when clustering of several PIV3 cases became manifest, all staff members were given further education on hygienic measures. However, we chose to preferably cohort all recognized PIV3-positive hematological patients in the Infectious Diseases Unit. One reason for this was the prospect of prolonged viral shedding in immunocompromised patients, and another that of asymptomatic carriage of PIV3 in additional patients and staff. We believe this strategy to have been beneficial for containing the spread of PIV3 in our unit. This assumption is supported by the finding that patients 5 and 8, with the most severe clinical disease and profound immunosuppression due to BMT from unrelated donor and associated GVHD, continued to shed the virus for several weeks (up to 38 days).
In the majority of our patients, PIV3 infection was diagnosed by means of viral antigen tests. Positive findings were phoned to the attending clinician often on the day of the admission of the patient, or the following day. Only on one occasion was the clinician informed of the positive PIV3 finding as late as the third hospital day, the delay being due to the weekend. Indeed, one major benefit afforded by the use of viral antigen tests as compared to viral culture, for example, involves the rapid availability of test results, rendering possible early commencement of antiviral therapy and implementation of appropriate hygiene measures in hospitalized patients.
PIV3 infection in an immunocompromised patient can be fatal, the prognosis being poor especially in BMT recipients with a lower respiratory tract infection. In this specific patient group, the mortality has varied between 30% and 50%. 4, 5, 7 Based on a few small series of patients and anecdotal case reports, antiviral treatment with ribavirin may improve the outcome of PIV3 infection. 4, 12, 13 Up to the present time, however, clinical efficacy of the drug in hematology patients has not been verified in controlled clinical studies. Of note here is the favorable outcome of all nine PIV3-infected patients, five of whom had undergone stem cell transplantation. The four patients who had infiltrates on their chest radiographs received intravenous ribavirin therapy. Thus, our data provide further evidence for the successful treatment of hematology patients with lower respiratory tract PIV3 infection with intravenous ribavirin. In previous studies, ribavirin has mainly been administered in aerosolized form. 4, 5, 9 This technique requires special equipment and is time-consuming, with 6 to 12 h daily inhalation time. 23, 24 In addition, the treatment may cause nausea, cough and even bronchial constriction, 13 which may be detrimental for a patient with threatened respiratory failure. Exposure of the personnel to inhaled ribavirin, with potential teratogenic effects is also of concern. 24 As compared to aerosolized ribavirin, administration of the drug intravenously is easy, though potentially inferior in clinical efficacy. However, there are reports showing that the intravenous form of ribavirin is effective in other respiratory virus infections, such as adenovirus pneumonia and pneumonitis. 25, 26 In conclusion, our experience shows that it may be possible to avoid mortality for PIV3 lower respiratory tract infection in BMT recipients and other hematological patients, provided that efforts are made to obtain a rapid etiologic diagnosis. It is also possible, even without closing the ward, to contain nosocomial spread of PIV3 in BMT units by implementing systematic nasopharyngeal sampling, by strict adherence to cohorting and contact isolation precautions and, when applicable, by cooperating with the infectious diseases unit when treating patients with PIV3 infections.
